📢 The PBM Landscape is Shifting: What You Need to Know The "black box" of PBM pricing is finally facing some serious federal sunlight. With the Consolidated Appropriations Act (CAA), we are seeing a massive regulatory pivot toward transparent, fee-based models—a move that could fundamentally change how our pharmacies are reimbursed. In the April 2026 edition of U.S. Pharmacist, Michael Dowell (Partner at Hinshaw) breaks down exactly what this means for our profession. While the headlines focus on "transparency," the devil is in the details of the upcoming compliance shifts. Key Takeaways for Pharmacists: Reimbursement Evolution: How the shift away from spread pricing might stabilize retail pharmacy margins. - The 2028-2029 Horizon: New reporting obligations that will force PBMs to disclose more than ever before. - Compliance Risks: Understanding the new regulatory hurdles for entities under the CAA. - Advocacy & Action: What we need to do now to prepare for these long-term changes. As the frontline of patient care, we know all too well how PBM practices impact our ability to serve our communities. It’s time to get ahead of the legislative curve. Read the full analysis in this month’s column: https://lnkd.in/emA2bQS7 #Pharmacy #PBMReform #HealthcareLaw #USPharmacist #PharmacyOwner #DrugPricing
The Consolidated Appropriations Act (CAA) introduces major reforms to pharmacy benefit manager (PBM) regulations, shifting toward transparent, fee-based PBM business models and creating new compliance risks for regulated entities. In a new column published in the April 2026 edition of U. S. Pharmacist, Hinshaw partner Michael Dowell discusses key regulatory changes, including new reporting obligations taking effect in 2028 and 2029, implications for retail and pharmacy reimbursement, compliance guidance, and more. Read his insights: https://lnkd.in/gxFX8xgC #HealthcareLaw #Pharmacy #PBM #Regulatory